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A b s t r a c t
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients 
with atrial fibrillation (AF) worldwide. Few articles have compared current understanding of AF patients about the disease and 
anticoagulant therapy in relation to the medications used.
Aim: We sought to compare the knowledge of AF and anticoagulation between AF patients treated with NOACs and those 
on vitamin K antagonists (VKAs). 
Methods: We used the Jessa AF Knowledge Questionnaire (JAKQ), developed and validated in Belgium. Patients were re-
cruited at a tertiary centre in Kraków, Poland.
Results: A total of 479 AF patients completed the JAKQ. Patients on NOACs (n = 276, 57.6%) compared with those on VKAs 
(n = 175, 36.5%) did not differ regarding demographic and clinical variables. The mean score of the JAKQ was very similar 
in the NOAC and VKA group (60.7 ± 17.0% vs. 61.6 ± 17.1%; p = 0.4, respectively). The differences in the proportion of 
correct responses referred to three questions. Consequences of AF, such as blood clots and cerebral infarction, were more 
obvious for patients on NOACs compared with those on VKAs (81.5% vs. 70.9%; p = 0.01). The patients on NOACs (78.7% 
vs. 67.6%; p = 0.009) more frequently considered consulting a physician for advice concerning anticoagulant treatment 
before surgery, while fewer patients on NOACs were aware of the need to take their medication even if they did not feel 
AF (76.1% vs. 89.7%; p = 0.0004). Only 25.9% of the VKA patients and 49.3% of the NOAC users knew what to do if they 
missed a dose of the anticoagulant. 
Conclusions: The knowledge of arrhythmia and anticoagulation is better regarding the safety issues among subjects on NOACs  
compared with those on VKAs. Irrespective of the type of oral anticoagulation therapy, education of AF patients should be improved.
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INTRODUCTION
The 2016 European Society of Cardiology (ESC) guidelines 
on the management of atrial fibrillation (AF) state that when 
oral anticoagulation (OAC) therapy is initiated in patients 
with AF (except for those with mechanical valve prosthesis or 
moderate-to-severe mitral stenosis), non-vitamin K antagonist 
oral anticoagulants (NOACs) are recommended in preference 
to vitamin K antagonists (VKAs) [1]. 
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Convenience in use and lack of the need for cumbersome 
routine monitoring have increased the number of patients tak-
ing NOACs, despite the lack of reimbursement and prohibitive 
costs, especially for the elderly [2]. 
Regardless of the benefits, any anticoagulant therapy is 
associated with an increased risk of haemorrhagic complica-
tions. Therefore, it is important to educate both the patient 
and the caregiver. The vital role of education in the efficacy 
and safety of OACs is underlined by the consensus of the 
European Heart Rhythm Association (EHRA) and the practi-
cal guidelines [3, 4]. So far, most articles that evaluated the 
AF patient’s understanding of the disease and therapy has 
focused on individuals taking VKAs [5–7]. 
Researchers from Hasselt University in Belgium devel-
oped and validated the Jessa AF Knowledge Questionnaire 
(JAKQ) to test the knowledge of patients with AF about this 
arrhythmia, its treatment, and the possibility of self-man-
agement [8]. The questionnaire seems to be an ideal tool 
to efficiently guide and target personalised education in AF 
patients, although its usefulness in other countries with dif-
ferent healthcare systems is unclear.
The aim of the current study was to evaluate knowledge 
gaps and current trends in OAC therapy in Polish patients with 
AF. Given the different reimbursement policies, OAC patterns 
with the predominance of acenocoumarol over warfarin 
among VKAs, and the lack of anticoagulation clinics in Poland, 
the present study was designed to confirm the usefulness of 
the JAKQ in another country. We sought to compare knowl-
edge of NOAC vs. VKA users with AF and determine factors 
affecting correct responses for key safety issues.
METHODS
Patients
We recruited patients with documented AF, who were referred 
to the John Paul II Hospital in Kraków (Poland), from Novem-
ber 2016 to May 2017. Eligible patients were > 18 years of age 
and were able to provide consent. We excluded unconscious 
patients or those in Intensive Care Units.
In the presence of the managing physicians, 513 patients 
with AF were asked to complete the questionnaire.
Questionnaire
We used the JAKQ from Hasselt University in Belgium after 
having obtained formal consent and performed its transla-
tion into Polish. The Questionnaire has been validated and 
described in detail previously [8]. This questionnaire con-
tained 16 questions. The study was in full compliance with 
the Declaration of Helsinki [8], and approval from the local 
Ethical Committee was obtained. 
Questionnaires were anonymous, and oral consent was 
obtained from each patient. The JAKQ consisted of multiple 
choice questions (four answers) with only one correct an-
swer. In each question there was an “I do not know” option 
to avoid guessing. A correct answer was scored as 1 point 
and an incorrect or “I do not know” answer was scored as 
0 points. Questionnaires were collected by doctors who 
completed general information about patients and medical 
data in a chart (Table 1). Completed charts were passed to 
an administrative official in our Hospital who collected and 
inputted data into a computer but was unaware of the aims 
of the survey. Data verification was performed subsequently 
by another person. The number of properly completed charts 
was 479 (93.4%). Twenty-five (4.9%) charts were excluded 
due to multiple answers, and nine (1.8%) were excluded be-
cause of insufficient clinical data. A total score was calculated 
from completed questions and displayed as the percentage. 
Clinical data
We collected relevant clinical data using an original ques-
tionnaire for clinicians participating in this study. We also 
documented the type of anticoagulation therapy with the drug 
dose, the presence of antiplatelet therapy (acetylsalicylic acid 
and/or clopidogrel), or history of VKA treatment in the past. 
We asked about the presence and type of diabetes, heart 
failure, and vascular disease. Valve replacement denoted the 
presence of an implanted cardiac mechanical valve prosthe-
sis. Mitral stenosis was defined according to the ESC guidelines 
and classified from mild to severe. Major bleeding events were 
defined according to Schulman et al. [9].
Statistical analysis
Continuous variables were presented as means (standard 
deviation) or median (interquartile range) as appropriate. 
The Kolmogorov-Smirnov test was used to determine the 
normal distribution of variables. Categorical variables were 
reported as numbers and percentages. The c2 test was used to 
compare categorical variables. The ANOVA or Kruskal-Wallis 
tests for continuous variables were used to assess differences 
between the groups. Multivariate logistic regression analysis 
was conducted to determine which variables were significant 
predictors of correct responses to selected questions. Back-
ward logistic regression was applied. Statistical analyses were 
performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA). 
P-values < 0.05 were accepted as statistically significant. 
RESULTS
Characteristics of the sample studied 
A total of 479 patients with AF were included in the final 
analysis (Table 1). 
There were 175 (36.5%) patients treated with VKAs 
(82 [17.1%] on warfarin and 93 [19.4%] on acenocoumarol) 
and 276 (57.6%) patients treated with NOACs. As few as 
10 (2.1%) patients received low-molecular-weight heparin 
at therapeutic or intermediate doses as stroke prophylaxis, 
while two (0.4%) subjects were taking acetylsalicylic acid 
75 mg/day in monotherapy. Sixteen (3.3%) patients did not 
receive any antithrombotic treatment on the day of complet-
ing the questionnaire. 
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Heart failure, mostly New York Heart Association 
(NYHA) class II or III, and history of myocardial infarction 
were observed more commonly among men compared with 
women (49.1% vs. 32.5%; p < 0.001 and 27.8% vs. 13. 6%; 
p < 0.001, respectively). Easy bruising on the current anti-
coagulant therapy was more frequently reported by women 
(57.7% vs. 28.9%; p < 0.001) with no difference for gingival 
bleeding between the two sexes.
General results
The median percentage of correct responses was 62.5 (50–75; 
minimum 6.2% and maximum 93.7%). 
An inverse correlation between age and the percentage 
of correct responses was observed (r = –0.18, p = 0.01). 
Women scored better than men, although they were older 
(66.7% [50–75] vs. 60% [50–68.8]; p = 0.01). Also, patients 
with mitral stenosis (68.8% [62.5–75] vs. 62.5% [50–75]; 
p = 0.05) and gingival bleeding (68.8% [53.3–75] vs. 62.5% 
[50–75]; p = 0.040) achieved better results. 
Individuals with a history of myocardial infarction (62.5% 
[50–75] vs. 60% [46.7–68.8]; p = 0.01) and vascular dis-
ease scored lower on the JAKQ (56.3% [50–68.6] vs. 66.7% 
[51.7–75]; p < 0.001). 
Most of the patients responded correctly to the ques-
tion about the definition of AF (76.2%), possible thrombotic 
consequences of the arrhythmia (77.7%), and the purpose of 
anticoagulant therapy (80.6%). There was also good knowl-
edge about the time interval for international normalised 
ratio (INR) control (93.6%) and the definition of INR (90%). 
As shown in Table 2, about one-third of AF patients 
knew that AF is not always symptomatic (34.4%) or that 
they should not consult a physician every time they feel it 
(30.3%). Furthermore, only 35.5% of patients perceived AF as 
a progressive condition. Of note, half of the patients did not 
know how to detect AF or which painkillers are the safest in 
combination with anticoagulants (Table 2). However, women 
were better informed about the safest painkillers and the 
progressive nature of AF (58.3% vs. 41.7%; p = 0.0005 and 
43.4% vs. 30.2%; p = 0.004, respectively).
Knowledge of AF patients on VKAs vs. NOACs 
The AF patients on NOACs versus those on VKAs were similar 
regarding demographics. Larger proportions of patients with 
paroxysmal and persistent AF treated for a shorter period with 
anticoagulants were observed in the NOAC group (Table 1). 
Heart failure (35.9% vs. 53.1%; p = 0.0004) and mitral 
Table 1. Characteristics of the study population
All  
(n = 479)
Patients treated with 
VKAs (n = 175)
Patients treated with 
NOACs (n = 276)
p
Age [years] 69.2  ± 10.8 69.6  ± 11.0 68.0  ± 10.5 0.4
Male sex 273 (57.0%) 104 (59.4%) 150 (54.3%) 0.3
Type of AF: < 0.001
Paroxysmal 204 (42.6%) 57 (32.6%) 130 (47.1%)
Persistent 75 (15.6%) 8 (4.6%) 66 (23.9%)
Permanent 200 (41.8%) 110 (62.9%) 80 (29.0%)
Time interval since AF diagnosis [months] 48 (14–100) 90 (48–144) 26 (10–60) < 0.001
Time interval since initiating the OAC [months] 24 (8–55) 72 (36–120) 12 (5–24) < 0.001
Comorbidities:
Heart failure 201 (42.0%) 93 (53.1%) 99 (35.9%) 0.0004
Arterial hypertension 409 (85.4%) 147 (84.0%) 241 (87.3%) 0.3
Diabetes mellitus 168 (35.1%) 69 (39.4%) 94 (34.1%) 0.3
Valve replacement 40 (8.4%) 39 (22.3%) 1 (0.4%) < 0.001
Mitral stenosis 11 (2.3%) 7 (4.0%) 3 (1.1%) 0.04
Prior myocardial infarction 104 (21.7%) 40 (22.9%) 57 (20.7%) 0.59
Prior stroke or TIA 82 (17.1%) 24 (13.7%) 55 (19.9%) 0.09
Vascular disease 151 (31.5%) 65 (37.1%) 82 (29.7%) 0.1
History of major bleeding 50 (10.4%) 11 (6.3%) 30 (10.9%) 0.1
Easy bruising 198 (41.3%) 87 (59.7%) 104 (37.7%) 0.01
Gingival bleeding 79 (16.5%) 31 (17.7%) 45 (16.3%) 0.7
Data are given as mean ± standard deviation, median (interquartile range), or number (percentages). AF — atrial fibrillation; NOACs — non-
-vitamin K antagonist oral anticoagulants; OAC — oral anticoagulation; TIA — transient ischaemic attack; VKAs — vitamin K antagonists
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stenosis (1.1% vs. 4.0%, p = 0.04) were observed less com-
monly among NOAC users. All patients with mitral stenosis 
treated with NOACs had a mild degree of valve disease. 
The risk of bleeding was similar in both groups; nonethe-
less, intense bruising was less frequently reported on NOAC 
treatment compared with VKA (37.7% vs. 59.7%; p = 0.01). 
Table 2. Specific topics addressed in the Jessa AF Knowledge Questionnaire (JAKQ) with the percentage of correct responses 
among AF patients treated with VKAs and NOACs
All  
(n = 479) 
VKA patients  
(n = 175) 
NOAC patients 
(n = 276) 
p
Eight questions about AF in general
AF is a condition where the heart beats irregularly and often  
faster than normal
365 (76.2%) 134 (76.6%) 209 (75.7%) 0.8
AF is not always accompanied by symptoms 165 (34.4%) 53 (30.3%) 99 (35.9%) 0.3
Patients can detect AF by taking their pulse regularly 240 (50.1%) 81 (46.3%) 145 (52.5%) 0.18
AF can cause blood clots that can lead to stroke (cerebral infarction) 372 (77.7%) 124 (70.9%) 225 (81.5%) 0.01
Medication cannot prevent AF permanently because the arrhythmia  
will increasingly occur with ageing, even when taking medication 
170 (35.5%) 66 (37.7%) 96 (34.8%) 0.5
An AF patient should not go to the general practitioner or  
emergency room each time he/she feels AF 
145 (30.3%) 60 (34.3%) 74 (26.8%) 0.1
Being overweight exacerbates AF 259 (54.9%) 91 (52.9%) 154 (56.6%) 0.44
Blood thinners are often prescribed for patients with AF in order to 
prevent the development of blood clots in the heart, which can lead  
to stroke 
386 (80.6%) 136 (77.7%) 227 (82.2%) 0.2
Five questions about OAC therapy
Patients with AF should always take their blood thinners,  
even if they do not feel AF 
387 (80.8%) 157 (89.7%) 210 (76.1%) 0.0004
Possible side effects of blood thinners are the occurrence of  
bleedings and longer bleeding times in case of injuries 
353 (73.7%) 127 (72.6%) 206 (74.6%) 0.7
AF patients may only take painkillers based on paracetamol 227 (47.4%) 88 (50.3%) 128 (46.4%) 0.5
When AF patients regularly have minor nose bleeds (that spontaneously 
cease), they should contact the general practitioner or specialist, while 
continuing to take their blood thinner
336 (71.5%) 127 (73.8%) 191 (71.2%) 0.4
If an AF patient needs an operation, he/she should consult a doctor  
to discuss possible options
348 (73.9%) 117 (67.6%) 214 (78.7%) 0.009
Three questions about VKA 
AF patients taking VKA should have their blood thinning checked  
at least once a month 
236 (93.6%) 163  (93.7%) 73 (93.6%)* 0.99
When AF patients taking VKA have forgotten to take their blood  
thinner, they should still take their forgotten pill (immediately  
or at the next dose)
65 (25.9%) 41 (23.7%) 24 (30.8%)* 0.3
INR is a measure to check how thick or how thin the blood is 225 (90.0%) 153 (88.4%) 72 (93.5%)* 0.2
Three questions about NOAC
For patients taking NOAC, it is important to take their blood thinner  
at the same time every day 
250 (92.3%)
When AF patients taking NOAC have forgotten to take their blood  
thinner, they can still take that dose, unless the time till the next  
dose is less than the time since the missed dose
134 (49.3%)
The NOAC card should be shown to their general practitioner  
and specialist by AF patients 
53 (26.4%)
*VKA used in the past; INR — international normalised ratio, other abbreviations — see Table 1
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There was no difference in the distribution of correct 
answers between NOAC and VKA patients (Fig. 1). The 
mean score on the JAKQ was 60.7% ± 17.0% in the NOAC 
group and 61.6% ± 17.1% in the VKA group (p = 0.4). We 
observed significant differences solely in responses to three 
questions. Consequences of the arrhythmia, such as blood 
clots and cerebral infarction, were more obvious for patients 
on NOACs (81.5% vs. 70.9%; p = 0.01). This group would 
also more frequently consider consulting a physician before 
an operation to discuss possible options concerning their OAC 
medication (78.7% vs. 67.6%; p = 0.009) (Table 2). However, 
NOAC users were less conscious about the importance of 
a regular anticoagulant intake despite the lack of symptoms 
(76.1% vs. 89.7%; p = 0.0004). Of note, as few as 26.4% 
of NOAC patients reported receiving a safety information 
card when starting OAC treatment and were familiar with 
its purpose.
Knowledge of AF patients on three different NOACs
In the NOAC group, 142 (51.4%) patients were taking ri-
varoxaban, 114 (41.3%) subjects were on dabigatran, and 
20 (7.2%) patients were on apixaban. Eighty-seven (31.5%) 
individuals receiving NOACs were previously treated with 
VKA. Reduced NOAC doses were recorded in 47 (33.0%) 
patients receiving rivaroxaban (15 mg daily), in 43 (37.7%) 
patients on dabigatran (110 mg twice daily), and in 12 (60.0%) 
individuals on apixaban (2.5 mg twice daily). 
Comparison of AF patients on three NOACs showed 
similar demographic and clinical characteristics except for the 
duration of anticoagulation therapy (the shortest for apixaban, 
p < 0.001), previous major bleeding (p < 0.01), and current 
gingival bleeding (p = 0.03). Of note, the two latter features 
were more frequently observed in the apixaban group, indicat-
ing that this agent was preferentially used in high-bleeding-risk 
subjects (Suppl. Table 1 — see journal website). 
Knowledge of AF patients on three different NOACs was 
similar (Suppl. Table 2 — see journal website). Any differ-
ences were observed only in the OAC treatment section. All 
patients taking apixaban were aware of possible bleedings 
during anticoagulation, but only 60% knew that they should 
take OAC regularly even in the absence of AF symptoms 
(p < 0.001). 
Figure 1. Distribution of correct responses in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs) and 
vitamin K antagonists (VKAs)
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Predictors of correct answers to selected questions 
We chose three questions regarding the safety issues and 
analysed factors that determined correct responses to them.
Only 47.4% of the AF patients were aware that the safest 
painkiller in combination with OAC therapy is paracetamol. 
Demographic factors that related to more correct responses 
in the whole group were: female sex (odds ratio [OR] 1.77; 
95% confidence interval [CI] 1.20–2.60; p = 0.004), outpa-
tient status (OR 2.24; 95% CI 1.51–3.23; p < 0.001), gingival 
bleeding (OR 2.06; 95% CI 1.21–3.49; p = 0.008), and valve 
replacement (OR 2.79; 95% CI 1.34–5.79; p = 0.006).
As few as 23.7% of the VKA patients knew what to do 
when they missed an OAC dose. Factors associated with cor-
rect response among VKA patients were age (OR 0.97; 95% 
CI 0.94–0.99; p = 0.012) and diabetes mellitus (OR 2.23; 
95% CI 1.23–4.03; p = 0.008). 
A similar question regarding the missed OAC dose was 
answered correctly by 49.3% of the NOAC users. Outpatients 
had significantly more correct responses (OR 3.27; 95% CI 
1.95–5.49; p < 0.001), whereas the presence of gingival 
bleeding (OR 2.00; 95% CI 0.97–4.11; p = 0.06) and the lack 
of vascular disease (OR 1.66; 95% CI 0.95–2.92; p = 0.078) 
showed borderline statistical significance (Table 3).
DISCUSSION
The present study compared the knowledge about arrhyth-
mia and its treatment among NOAC vs. VKA users with 
AF and demonstrated the usefulness of the JAKQ in Polish 
patients. We expanded observations published by Desteghe 
et al. [8], by showing that despite the fact that NOACs were 
only introduced a couple of years ago in daily practice, the 
knowledge of patients receiving this group of medications was 
similar to that of subjects on VKAs. Nevertheless, the use of 
NOACs was associated with more correct responses for most 
key safety questions in the JAKQ. Remarkably, most of our 
patients receiving NOACs knew that it is important to take 
their blood thinner at the same time every day. The patients on 
NOACs would more frequently consider getting medical ad-
Table 3. Predictors of correct responses to three key questions related to the safety of anticoagulation
  AF patients may  
only take painkillers 
based on paracetamol
When AF patients taking NOAC 
have forgotten to take their 
blood thinner, they can still take 
that dose, unless the time till 
the next dose is less than the 
time since the missed dose
When AF patients taking VKA 
have forgotten to take their 
blood thinner, they should still 
take their forgotten pill  
(immediately or at the 
next dose)
  OR 95% CI p OR 95% CI p OR 95% CI p
Age  0.97 0.94–0.99 0.012
Sex:
Male 1 1.20–2.60 0.004
Female 1.77
Hospital:
Hospital 1 1
Outpatients  2.24 1.51–3.23 < 0.001 3.27 1.95–5.49 < 0.001
Diabetes mellitus:
No 1
Yes   2.23 1.23–4.03 0.008
Gingival bleeding:
No 1
Yes 2.06 1.21–3.49 0.008 2.00 0.97–4.11 0.06
Valve replacement:
No
Yes 2.79 1.34–5.79 0.006    
Vascular disease:
Yes 1
No     1.66 0.95–2.92 0.078
CI — confidence interval; OR — odds ratio; other abbreviations — see Table 1
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vice about anticoagulant treatment before surgery. Knowledge 
of AF patients on rivaroxaban, dabigatran, and apixaban was 
similar. This held true also for VKA-naïve patients on NOACs 
and those previously receiving VKAs. We also identified 
predictors of correct responses for these relevant questions, 
highlighting the need for additional educational interventions.
Similarly to the study by Desteghe et al. [8], Polish patients 
had a satisfactory level of knowledge about the definition of 
AF, its consequences, and the necessity of anticoagulation 
therapy. However, there was no question answered correctly 
by all patients and there were still different knowledge gaps 
in these patients. The proportions of correct responses in 
other studies that evaluated the knowledge of AF patients 
were lower [6, 10]. This suggests that with time, in 2017, the 
knowledge about AF and stroke prevention has improved. In 
a multi-ethnic study published in 2002, 37% of subjects were 
not aware of their AF diagnosis and 47% did not recognise 
that having AF put them at an increased risk of stroke [11]. In 
our study the consequences of the arrhythmia, such as blood 
clots and cerebral infarction, were more obvious for patients 
on NOACs, presumably because the attending physicians em-
phasise the benefits of using new, more expensive drugs. VKA 
users were treated significantly longer; also, the vital role of 
education, and the indication to discuss with patients the 
choice of OAC, including the safety issues, were emphasised 
as late as in the ESC guidelines from 2016 [1]. 
Although our results highlight some major knowledge gaps 
among VKA users, we found that most of our patients on VKA 
were aware of the mandatory monthly INR monitoring. Our 
results were better compared with the study by Desteghe et 
al. [8] and the EHRA study, with lower proportions of correct 
responses (81% and 76%, respectively) [12]. 
Regarding the gender issue, we observed that women 
with AF scored better than men, although they were older. 
This finding disagrees with Desteghe et al. [8], who failed to 
observe any gender-related differences. It might be speculated 
that this difference is associated with a better health status in 
women because heart failure and prior myocardial infarction 
were less frequent among them in the current study. Inter-
estingly, women were also better informed about the safest 
painkillers during OAC use. It has been reported that there 
is more frequent use of painkillers in women, hence their 
greater awareness of this problem might be associated with 
higher scores observed by us. 
The novelty of our study was to identify the factors as-
sociated with correct responses to selected questions about 
safety issues of OAC therapy. Patients who correctly indicated 
painkillers were more often outpatients, women, and had 
a history of valve replacement or gingival bleeding. This may 
be related to greater caution when using various drugs by those 
who have had concomitant diseases and minor bleeding. 
Those with prosthetic heart valves were found to be better 
informed about OAC. In our hospital those patients receive an 
OAC guide with a discharge card and they also have regular 
outpatient visits, which probably has a great impact on their 
knowledge in this field.
Regarding the current trends in anticoagulant therapy in 
AF patients, we showed that a large proportion of subjects is 
receiving NOACs (predominantly rivaroxaban), even though 
patients with AF are not reimbursed for these medications in 
Poland. Interestingly, among patients treated with NOACs, 
only one-third previously received VKAs. Desteghe et al. [8] 
also demonstrated that 64.4% of the entire AF population 
used NOACs. In the study conducted by EHRA in 2015 among 
patients from eight European countries, NOAC use ranged 
from 31.9% in Swedish patients to 8.2% in Norway. There 
were regional differences regarding the preference of a certain 
NOAC [13]. The use of rivaroxaban and dabigatran among 
our NOAC users with AF (51.4% vs. 41.3%, respectively) 
was similar to the results of the multicentre NOAC-TURK 
study published in 2017, in which 39.6% of patients were 
on rivaroxaban and 38.1% were treated with dabigatran [14]. 
Of note, in the present study, reduced NOAC doses 
were recorded in a substantial proportion of patients, and 
it appears to be larger than that reported in previous studies 
[15–17]. As expected, our patients receiving reduced doses 
of NOACs were older and had a history of previous bleed-
ing. Therefore, our data reflect a common everyday practice 
to prescribe reduced doses of NOACs in high-bleeding-risk 
patients with AF. However, it is advisable to stick to the current 
ESC guidelines and prescribe lower NOAC doses according 
to the current recommendation, i.e. mainly in individuals 
with renal impairment [1]. Exploration of the reasons for such 
lower doses of NOACs in our cohort was beyond the scope 
of the current study.
The popularity of NOACs among Polish AF patients is 
probably related to the advantages of their use as compared 
to VKAs. NOACs are easier to administer because they can be 
given in fixed doses without the need for laboratory monitoring 
[18]. Since in Poland the quality of anticoagulation treatment is 
rather low due to the lack of anticoagulation clinics [2], physi-
cians encourage patients to use NOACs, despite their high cost, 
in order to increase the efficacy and possibly safety of long-term 
anticoagulation. Our study compellingly demonstrates that 
NOACs are an attractive therapeutic option preferred by pa-
tients even if there is no favourable reimbursement policy and 
the cost of their use is substantial, as in Poland. 
The study has several limitations. It was conducted at 
a hospital dealing with cardiovascular disease with well- 
-organised clinics for outpatients with thrombotic diseases and 
OAC complications; therefore, our results could not be easily 
translated to primary care or other hospitals.
We did not analyse the effect of the patients’ level of 
education on AF-related knowledge. A larger multinational 
study is needed to identify key knowledge gaps among AF 
patients to improve everyday care.
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In conclusion, we observed that the knowledge about 
AF and OAC is similar between subjects on VKAs and 
NOACs. However, there is better knowledge regarding the 
safety issues in the latter group. Irrespective of the type of 
OAC therapy, education of AF patients should be improved, 
with particular emphasis on the safety issues of this treatment.
Conflict of interest: Małgorzata Konieczyńska has taken part 
in conferences sponsored by Bayer and Boehringer Ingelheim; 
Piot Podolec, Anetta Undas have received lecture honoraria 
from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, 
Sanofi-Aventis; Hein Heidbuchel has been a member of the 
scientific advisory boards and lecturer for Boehringer Ingelheim, 
Bayer, Bristol Myers Squibb, Pfizer, Daiichi-Sankyo; Andrzej 
Pająk received personal fees from AMGEN and Sanofi, not 
related to submitted work.
References
1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines 
for the management of atrial fibrillation developed in col-
laboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962, 
doi: 10.1093/eurheartj/ehw210, indexed in Pubmed: 27567408.
2. Undas A, Pasierski T, Windyga J, et al. Practical aspects of new 
oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn. 
2014; 124(3): 124–135, doi: 10.20452/pamw.2138, indexed in 
Pubmed: 24556890.
3. Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac 
tachyarrhythmias and patient values and preferences for their 
management: the European Heart Rhythm Association (EHRA) 
consensus document endorsed by the Heart Rhythm Society 
(HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad 
Latinoamericana de Estimulación Cardíaca y Electrofisiología 
(SOLEACE). Europace. 2015; 17(12): 1747–1769, doi: 10.1093/eu-
ropace/euv233, indexed in Pubmed: 26108807.
4. Heidbuchel H, Verhamme P, Alings M, et al. Updated Euro-
pean Heart Rhythm Association practical guide on the use 
of non-vitamin-K antagonist anticoagulants in patients with 
non-valvular atrial fibrillation: Executive summary. Eur Heart J. 
2017; 38(27): 2137–2149, doi: 10.1093/eurheartj/ehw058, indexed 
in Pubmed: 27282612.
5. Smith DE, Xuereb CB, Pattison HM, et al. TRial of an Educational 
intervention on patients’ knowledge of Atrial fibrillation and 
anticoagulant therapy, INR control, and outcome of Treatment 
with warfarin (TREAT). BMC Cardiovasc Disord. 2010; 10: 21, 
doi: 10.1186/1471-2261-10-21, indexed in Pubmed: 20487528.
6. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and 
perceptions of atrial fibrillation and anticoagulant therapy: 
effects of an educational intervention programme. The West 
Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006; 
110(3): 354–358, doi: 10.1016/j.ijcard.2005.07.031, indexed in 
Pubmed: 16253356.
7. Clarkesmith D, Pattison H, Lip G, et al. Educational Intervention 
Improves Anticoagulation Control in Atrial Fibrillation Patients: 
The TREAT Randomised Trial. PLoS ONE. 2013; 8(9): e74037, 
doi: 10.1371/journal.pone.0074037.
8. Desteghe L, Engelhard L, Raymaekers Z, et al. Knowledge gaps 
in patients with atrial fibrillation revealed by a new validated 
knowledge questionnaire. Int J Cardiol. 2016; 223: 906–914, 
doi: 10.1016/j.ijcard.2016.08.303, indexed in Pubmed: 27589038.
9. Schulman S, Kearon C. Definition of major bleeding in clinical 
investigations of antihemostatic medicinal products in non-sur-
gical patients. J Thromb Haemost. 2005; 3(4): 692–694, doi: 10.1
111/j.1538-7836.2005.01204.x, indexed in Pubmed: 15842354.
10. McCabe PJ, Schad S, Hampton A, et al. Knowledge and 
self-management behaviors of patients with recently detected 
atrial fibrillation. Heart Lung. 2008; 37(2): 79–90, doi: 10.1016/j.
hrtlng.2007.02.006, indexed in Pubmed: 18371501.
11. Lip G, Kamath S, Jafri M, et al. Ethnic differences in patient 
perceptions of atrial fibrillation and anticoagulation therapy: the 
West Birmingham Atrial Fibrillation Project. Stroke. 2002; 33(1): 
238–242, doi: 10.1161/hs0102.101817.
12. Amara W, Larsen TB, Sciaraffia E, et al. Patients’ attitude 
and knowledge about oral anticoagulation therapy: results of 
a self-assessment survey in patients with atrial fibrillation con-
ducted by the European Heart Rhythm Association. Europace. 
2016; 18(1): 151–155, doi:  10.1093/europace/euv317, indexed 
in Pubmed: 26462697.
13. Madrid AH, Potpara TS, Dagres N, et al. Differences in at-
titude, education, and knowledge about oral anticoagulation 
therapy among patients with atrial fibrillation in Europe: result 
of a self-assessment patient survey conducted by the European 
Heart Rhythm Association. Europace. 2016; 18(3): 463–467, 
doi: 10.1093/europace/euv448, indexed in Pubmed: 26899998.
14. Altay S, Yıldırımtürk Ö, Çakmak HA, et al. NOAC-TURK Study 
Collaborators. New oral anticoagulants-TURKey (NOAC-TURK): 
Multicenter cross-sectional study. Anatol J Cardiol. 2017; 17(5): 
353–361, doi:  10.14744/anatoljcardiol.2016.7472, indexed in 
Pubmed: 28100898.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Com-
mittee and Investigators. Dabigatran versus warfarin in patients 
with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151, 
doi: 10.1056/NEJMoa0905561, indexed in Pubmed: 19717844.
16. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investiga-
tors. Rivaroxaban versus warfarin in nonvalvular atrial fibrilla-
tion. N Engl J Med. 2011; 365(10): 883–891, doi: 10.1056/NEJ-
Moa1009638, indexed in Pubmed: 21830957.
17. Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE 
Committees and Investigators. Apixaban versus warfarin in pa-
tients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992, 
doi: 10.1056/NEJMoa1107039, indexed in Pubmed: 21870978.
18. Undas A. Long-term anticoagulation in questions and  an-
swers. Pol Arch Med Wewn. 2016; 126(12): 1036–1039, 
doi: 10.20452/pamw.3773, indexed in Pubmed: 28010011.
www.kardiologiapolska.pl
Małgorzata Konieczyńska et al.
1096
